Ticker: ELV

Elevance

Healthcare Healthcare Medical - Healthcare Plans

Price 422.02

Reco Buy Potential 69 Risk 46 Updated 2026-10-29

Official website

Forecast impact

positive

Target +25.5% target fill 79.7%

Reaction D5 -8.05% · D10 pending market trust

Impact Potential +3 · Risk -1 valid until 2026-11-22

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Elevance Health, Inc. operates in the healthcare sector, primarily providing managed care services. Its core products include health insurance plans and related services, targeting individuals, families, and employers. Major business segments encompass Commercial and Government segments, with significant revenue derived from premiums and service fees. The company focuses on improving health outcomes while managing costs through innovative healthcare solutions.

Investment Profile

Elevance's stock presents a profile that may appeal to balanced investors, given its combination of growth potential and dividend yield. The company's consistent revenue growth and moderate volatility suggest a stable investment environment. The dividend yield of 2.2% adds an income component, making it suitable for those seeking both capital appreciation and regular income.

Category: Healthcare Sector: Healthcare Industry: Medical - Healthcare Plans Investment style: Growth Horizon: Medium-term Company type: Blue Chip Company type: Large Cap Experience: Basic

Fundamental metrics (experimental) Updated: 2026-10-29

EPS (TTM) — earnings per share for the last 12 months, $: 23.51
Revenue QoQ — quarter-over-quarter revenue growth: 0.9%
EPS surprise: 14.1%
20d volatility: 1.5%
Dividend yield: 1.6%
last ex-date: 2026-06-10

AI recommendation changes

Date	Before	After	Reason
2026-10-09	Hold	Buy	Solid fundamentals, but mixed momentum signals present uncertainty.
2026-10-01	Buy	Hold	Weak momentum and mixed signals suggest caution.
2026-08-08	Hold	Buy	Strong performance and positive EPS surprise support growth outlook.
2026-07-31	Buy	Hold	Mixed momentum and fundamentals warrant caution.
2026-07-22	Hold	Buy	Strong momentum and solid fundamentals support growth potential.
2026-07-16	Buy	Hold	Weak momentum and high risk; hold for now.
2026-05-08	—	Buy	Strong fundamentals, but mixed momentum signals.
2026-05-03	Buy	Hold	Компания Elevance Health демонстрирует стабильный рост выручки и положительные результаты по EPS, что указывает на сильные финансовые показатели. Умеренный риск связан с колебаниями на рынке, но текущие тренды и дивиденд
2026-04-25	Hold	Buy	Компания Elevance Health демонстрирует стабильный рост выручки и положительные показатели EPS, что свидетельствует о ее финансовой устойчивости. Учитывая дивидендную доходность и недавний рост акций, инвестиции в компани
2026-02-24	Buy	Hold	Компания показывает умеренный рост за последние 120 дней, однако недавние колебания цен и снижение выручки указывают на возможные риски. Рекомендуется удерживать акции до получения более ясных сигналов о восстановлении.
2026-02-16	Hold	Buy	Компания показывает стабильный рост в долгосрочной перспективе, однако недавнее снижение выручки и волатильность на рынке могут указывать на необходимость осторожности.
2026-01-29	Buy	Hold	Компания показывает положительную динамику на длительном горизонте, однако недавнее снижение на 7.58% за 5 дней вызывает опасения. Рекомендуется удерживать акции до более ясных сигналов о восстановлении.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-10-23	Piper Sandler	Target Raised	— → 520	442.85
2026-10-23	Mizuho Securities	Target Raised	470 → 490	445.28
2026-10-23	Goldman Sachs	Target Raised	395 → 451	445.28
2026-10-22	UBS	Target Raised	460 → 523	439.1022
2026-10-22	RBC Capital	Target Raised	424 → 455	441.21
2026-10-22	Guggenheim	Target Raised	460 → 485	434.13
2026-10-22	Robert W. Baird	Target Raised	393 → 406	434.13
2026-10-22	Barclays	Target Raised	469 → 472	434.13
2026-10-12	Guggenheim	Target Raised	— → 460	412.7
2026-10-07	Barclays	Target Raised	457 → 469	400.09
2026-07-17	Leerink Partners	Target Raised	364 → 395	369.28
2026-07-16	Bernstein	Target Raised	482 → 488	372.85
2026-07-16	New Street	Update	— → 482	377.63
2026-07-16	RBC Capital	Target Lowered	439 → 424	390.33
2026-07-16	Goldman Sachs	Target Raised	370 → 395	390.33
2026-07-16	Robert W. Baird	Target Raised	331 → 393	390.33
2026-07-16	Guggenheim	Target Raised	— → 455	390.33
2026-07-16	Wells Fargo	Target Lowered	492 → 473	390.33
2026-07-16	Barclays	Target Lowered	480 → 457	390.33
2026-07-14	Truist Financial	Target Raised	450 → 475	425.17
2026-07-13	Wells Fargo	Target Raised	391 → 492	416.23
2026-07-09	RBC Capital	Target Raised	358 → 439	425.9
2026-07-07	Raymond James	Target Raised	400 → 450	408.17
2026-07-02	Bernstein	Target Raised	424 → 482	416.19
2026-06-08	Mizuho Securities	Target Raised	435 → 465	415.53
2026-06-04	Morgan Stanley	Target Raised	352 → 404	391.27
2026-06-01	Truist Financial	Target Raised	375 → 450	393.19
2026-05-26	Barclays	Target Raised	408 → 480	386.87
2026-05-22	UBS	Target Raised	400 → 460	389.82
2026-05-20	Mizuho Securities	Target Raised	385 → 435	402.27
2026-05-20	Deutsche Bank	Rating Upgraded	— → 498	402.27
2026-04-24	Guggenheim	Target Raised	396 → 399	346.29
2026-04-24	Barclays	Target Raised	393 → 408	346.29
2026-04-23	Leerink Partners	Target Raised	357 → 364	346.21
2026-04-23	Robert W. Baird	Target Raised	317 → 331	328.2
2026-04-20	Jefferies	Target Lowered	395 → 391	323.05
2026-03-10	Mizuho Securities	Target Lowered	— → 350	282.68

News Page 1 of 1

Stocks Making Significant Moves Premarket: BlackRock, PayPal, ASML, and Others

07/15/2026, 04:37 AM investing review Elevance PayPal ASML BlackRock IBM M&T Bank Pentair Johnson & Johnson

Premarket trading saw significant movements in several major companies, with BlackRock and PayPal experiencing notable gains while Pentair and Elevance Health faced sharp declines. These fluctuations highlight the impact of earnings reports and acquisition interest on stock performance.